Evidence map›Paper›PMID 40119070›Full record

ArticleNPJ precision oncology2025

ARRB2 promotes cervical cancer progression via stabilizing CDC25A mRNA through m6A-IGF2BP1-dependent manner.

Lijie Li, Jie Zeng, Mengying Liu, Hui Cheng, Yuyin He, Sili He, Chen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The mMolecular biomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lijie LiDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Jie ZengNursing Department, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Mengying LiuDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Hui ChengDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Yuyin HeDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Sili HeDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China.
Chen WangDepartment of Gynecology, The Third Xiangya Hospital of Central South University, Changsha, P.R. China. 445056672@qq.com.ORCID http://orcid.org/0009-0008-5773-5522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer causes many deaths among women worldwide. Exploring the mechanisms underlying proliferation and metastasis contributes to developing novel intervention strategies. Here, we found that ARRB2 was highly expressed, and its increased expression was associated with poor prognosis of patients with cervical cancer. Knockdown of ARRB2 repressed the proliferation, migration, invasion and EMT of cervical cancer cells. Furthermore, CDC25A was upregulated, and ARRB2 stabilized CDC25A mRNA through IGF2BP1. CDC25A silencing inhibited proliferation, migration, and invasion, but it was reversed by ARRB2 overexpression. Silencing of CDC25A suppressed EMT signaling via promoting FOXO3 phosphorylation and cytoplasmic localization and inhibiting Snail1 transcription. Knockdown of ARRB2 suppressed tumor growth and metastasis through CDC25A downregulation. In conclusion, ARRB2 promotes FOXO3 nuclear translocation and Snail1 transcription by stabilizing CDC25A mRNA in an m6A-dependent manner, thus facilitating proliferation and metastasis in cervical cancer.

Identifiers

PMID40119070
PMCPMC11928456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.